busulfan has been researched along with Infection in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 7.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "Since 1997, 32 newly diagnosed multiple myeloma patients responsive to DAV chemotherapy were autografted with idarubicin-intensified busulphan-melphalan (ida-bu-mel)." | 7.73 | High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control. ( Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M, 2006) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 3.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "Since 1997, 32 newly diagnosed multiple myeloma patients responsive to DAV chemotherapy were autografted with idarubicin-intensified busulphan-melphalan (ida-bu-mel)." | 3.73 | High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control. ( Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M, 2006) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate." | 3.71 | A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. ( Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| "Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identical unrelated donors." | 3.69 | Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. ( Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D, 1996) |
| "The toxic effects of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) with autologous or syngeneic bone marrow rescue were evaluated in 19 patients (11 with acute myelocytic leukemia, one with acute lymphocytic leukemia, one with acute myelofibrosis, two with chronic myelocytic leukemia, one with Hodgkin's disease, and three with non-Hodgkin's lymphoma)." | 3.67 | Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. ( Braine, HG; Kaizer, H; Lu, C; Santos, GW; Saral, R; Tutschka, PJ, 1984) |
| "Besides high rates of manageable infections due to late immune recovery, transplantation with CD34+ immunoselected grafts in HRNB children was feasible and did not affect long-term hematopoiesis." | 2.76 | CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. ( Berger, M; Demeocq, F; Halle, P; Kanold, J; Leverger, G; Marabelle, A; Merlin, E; Paillard, C; Piguet, C; Rousseau, R; Stephan, JL; Tchirkov, A, 2011) |
| "Exacerbation of infection during aplasia was observed in 3 patients; inflammatory flare at the infection site during neutrophil engraftment in 2: all 5 patients belonged to the subgroup of 9 with pre-existing infection." | 2.41 | Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. ( Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F, 2002) |
| "Only viral infections were significantly increased in the non-TBI group." | 1.48 | Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. ( Anagnostopoulos, A; Apostolou, C; Athanasiadou, A; Batsis, I; Bousiou, Z; Bouziana, S; Chatziioannou, K; Constantinou, V; Douka, V; Gavriilaki, E; Gianouzakos, V; Iskas, M; Lalayanni, C; Mallouri, D; Papathanasiou, M; Sakellari, I; Sotiropoulos, D; Yannaki, E, 2018) |
| " Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient." | 1.30 | Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. ( Anasetti, C; Appelbaum, FR; Bensinger, WI; Bowden, R; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Deeg, HJ; Doney, KC; Flowers, M; Gooley, T; Hansen, JA; Martin, PJ; McDonald, GB; Nash, R; Petersdorf, EW; Radich, J; Sanders, JE; Schoch, G; Slattery, JT; Soll, E; Stewart, P; Storb, R; Storer, B; Sullivan, KM; Thomas, ED; Witherspoon, RP, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (20.59) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 13 (38.24) | 29.6817 |
| 2010's | 6 (17.65) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| D'Angelo, CR | 1 |
| Hall, A | 1 |
| Woo, KM | 1 |
| Kim, K | 2 |
| Longo, W | 1 |
| Hematti, P | 1 |
| Callander, N | 1 |
| Kenkre, VP | 1 |
| Mattison, R | 1 |
| Juckett, M | 1 |
| Modi, D | 1 |
| Singh, V | 1 |
| Kim, S | 1 |
| Ayash, L | 2 |
| Deol, A | 1 |
| Ratanatharathorn, V | 2 |
| Uberti, JP | 1 |
| Jung, SH | 1 |
| Lee, JJ | 1 |
| Kim, JS | 1 |
| Min, CK | 1 |
| Choi, Y | 1 |
| Eom, HS | 1 |
| Joo, YD | 1 |
| Kim, SH | 2 |
| Kwak, JY | 1 |
| Kang, HJ | 1 |
| Lee, JH | 3 |
| Lee, HS | 1 |
| Mun, YC | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Park, SK | 1 |
| Park, Y | 1 |
| Shin, HJ | 2 |
| Yoon, SS | 1 |
| Sakellari, I | 1 |
| Gavriilaki, E | 1 |
| Chatziioannou, K | 1 |
| Papathanasiou, M | 1 |
| Mallouri, D | 1 |
| Batsis, I | 1 |
| Bousiou, Z | 1 |
| Bouziana, S | 1 |
| Constantinou, V | 1 |
| Douka, V | 1 |
| Apostolou, C | 1 |
| Iskas, M | 1 |
| Lalayanni, C | 1 |
| Athanasiadou, A | 1 |
| Sotiropoulos, D | 1 |
| Yannaki, E | 1 |
| Gianouzakos, V | 1 |
| Anagnostopoulos, A | 1 |
| Mallhi, K | 1 |
| Orchard, PJ | 1 |
| Miller, WP | 1 |
| Cao, Q | 1 |
| Tolar, J | 1 |
| Lund, TC | 1 |
| Hamadani, M | 1 |
| Blum, W | 1 |
| Phillips, G | 1 |
| Elder, P | 1 |
| Andritsos, L | 1 |
| Hofmeister, C | 1 |
| O'Donnell, L | 1 |
| Klisovic, R | 1 |
| Penza, S | 1 |
| Garzon, R | 1 |
| Krugh, D | 1 |
| Lin, T | 1 |
| Bechtel, T | 1 |
| Benson, DM | 1 |
| Byrd, JC | 1 |
| Marcucci, G | 1 |
| Devine, SM | 1 |
| Ulrickson, M | 1 |
| Aldridge, J | 1 |
| Kim, HT | 1 |
| Hochberg, EP | 1 |
| Hammerman, P | 1 |
| Dube, C | 1 |
| Attar, E | 1 |
| Ballen, KK | 1 |
| Dey, BR | 1 |
| McAfee, SL | 1 |
| Spitzer, TR | 1 |
| Chen, YB | 1 |
| Atallah, E | 1 |
| Abrams, J | 1 |
| Bentley, G | 1 |
| Abidi, M | 1 |
| Uberti, J | 1 |
| Marabelle, A | 1 |
| Merlin, E | 1 |
| Halle, P | 1 |
| Paillard, C | 1 |
| Berger, M | 1 |
| Tchirkov, A | 1 |
| Rousseau, R | 1 |
| Leverger, G | 1 |
| Piguet, C | 1 |
| Stephan, JL | 1 |
| Demeocq, F | 1 |
| Kanold, J | 1 |
| Lee, KH | 1 |
| Kim, DY | 1 |
| Seol, M | 1 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Hwang, HJ | 1 |
| Jung, AR | 1 |
| Yun, SC | 1 |
| Seger, RA | 1 |
| Gungor, T | 1 |
| Belohradsky, BH | 1 |
| Blanche, S | 1 |
| Bordigoni, P | 1 |
| Di Bartolomeo, P | 1 |
| Flood, T | 1 |
| Landais, P | 1 |
| Müller, S | 1 |
| Ozsahin, H | 1 |
| Passwell, JH | 1 |
| Porta, F | 1 |
| Slavin, S | 3 |
| Wulffraat, N | 1 |
| Zintl, F | 1 |
| Nagler, A | 3 |
| Cant, A | 1 |
| Fischer, A | 1 |
| Saito, T | 1 |
| Kanda, Y | 1 |
| Nakai, K | 1 |
| Kim, SW | 1 |
| Arima, F | 1 |
| Kami, M | 1 |
| Tanosaki, R | 1 |
| Tobinai, K | 1 |
| Wakasugi, H | 1 |
| Heike, Y | 1 |
| Mineishi, S | 1 |
| Takaue, Y | 1 |
| Massenkeil, G | 1 |
| Nagy, M | 1 |
| Le Coutre, P | 1 |
| Heine, F | 1 |
| Rosen, O | 1 |
| Dörken, B | 1 |
| Arnold, R | 1 |
| Capria, S | 1 |
| Petrucci, MT | 1 |
| Pulsoni, A | 1 |
| Ribersani, M | 1 |
| Baldacci, E | 1 |
| de Propris, MS | 1 |
| Meloni, G | 1 |
| Kiefer, T | 1 |
| Krüger, WH | 1 |
| Schüler, F | 1 |
| Lotze, C | 1 |
| Hirt, C | 1 |
| Dölken, G | 1 |
| Rodriguez, R | 1 |
| Nademanee, A | 1 |
| Ruel, N | 1 |
| Smith, E | 1 |
| Krishnan, A | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Patane, K | 1 |
| Kogut, N | 1 |
| Nakamura, R | 1 |
| Sarkodee-Adoo, C | 1 |
| Forman, SJ | 1 |
| Lu, C | 1 |
| Braine, HG | 1 |
| Kaizer, H | 1 |
| Saral, R | 1 |
| Tutschka, PJ | 1 |
| Santos, GW | 1 |
| Deeg, HJ | 4 |
| Storb, R | 2 |
| Prentice, R | 1 |
| Fritz, TE | 1 |
| Weiden, PL | 1 |
| Sale, GE | 1 |
| Graham, TC | 1 |
| Thomas, ED | 4 |
| Clift, RA | 4 |
| Buckner, CD | 4 |
| Bryant, E | 4 |
| Anasetti, C | 3 |
| Bensinger, WI | 4 |
| Bowden, R | 3 |
| Doney, KC | 3 |
| Fisher, LD | 2 |
| Casper, J | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Baxter-Lowe, LA | 1 |
| Bunin, N | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Pietryga, D | 1 |
| Garbrecht, F | 1 |
| Hansen, JA | 2 |
| Anderson, JE | 1 |
| Appelbaum, FR | 2 |
| Schoch, G | 2 |
| Gooley, T | 2 |
| Chauncey, T | 2 |
| Topolsky, D | 1 |
| Crilley, P | 1 |
| Styler, MJ | 1 |
| Bulova, S | 1 |
| Brodsky, I | 1 |
| Marks, DI | 1 |
| Slattery, JT | 1 |
| Radich, J | 1 |
| Storer, B | 1 |
| Soll, E | 1 |
| Flowers, M | 1 |
| Martin, PJ | 1 |
| McDonald, GB | 1 |
| Nash, R | 1 |
| Petersdorf, EW | 1 |
| Sanders, JE | 1 |
| Stewart, P | 1 |
| Sullivan, KM | 1 |
| Witherspoon, RP | 1 |
| Varadi, G | 2 |
| Naparstek, E | 2 |
| Samuel, S | 1 |
| Or, R | 2 |
| Bornhäuser, M | 1 |
| Thiede, C | 1 |
| Schuler, U | 1 |
| Platzbecker, U | 1 |
| Freiberg-Richter, J | 1 |
| Helwig, A | 1 |
| Plettig, R | 1 |
| Röllig, C | 1 |
| Naumann, R | 1 |
| Kroschinsky, F | 1 |
| Neubauer, A | 1 |
| Ehninger, G | 1 |
| Openshaw, H | 1 |
| Lund, BT | 1 |
| Kashyap, A | 1 |
| Atkinson, R | 1 |
| Sniecinski, I | 1 |
| Weiner, LP | 1 |
| Forman, S | 1 |
| Morecki, S | 1 |
| Gelfand, Y | 1 |
| Engelhard, D | 1 |
| Akerstein, A | 1 |
| Kröger, N | 1 |
| Schetelig, J | 1 |
| Zabelina, T | 1 |
| Krüger, W | 1 |
| Renges, H | 1 |
| Stute, N | 1 |
| Schrum, J | 1 |
| Kabisch, H | 1 |
| Siegert, W | 1 |
| Zander, AR | 1 |
| Thompson, EN | 1 |
| Soothill, JF | 1 |
| Seidel, HJ | 1 |
| Ward, HP | 1 |
| Block, MH | 1 |
| Saslaw, S | 1 |
| Carlisle, HN | 1 |
| Marcovitch, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms[NCT01707004] | Phase 2 | 20 participants (Actual) | Interventional | 2013-05-16 | Completed | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT[NCT02677181] | Phase 4 | 100 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies[NCT01295762] | 35 participants (Actual) | Interventional | 2011-05-31 | Active, not recruiting | |||
| NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430] | 30 participants (Anticipated) | Interventional | 2004-04-30 | Completed | |||
| HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY[NCT00732316] | Phase 2 | 54 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY[NCT01795378] | Phase 1/Phase 2 | 56 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Will be summarized with a proportion and a 95% confidence interval. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | percentage (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 40.7 |
Determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN). Will be analyzed using KM method, a Graft versus Host Disease (GVHD) grade III-IV will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 27.8 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 14 |
Defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation. Will be analyzed using KM method. (NCT01707004)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 0 |
Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 64.7 |
Platelet recovery is defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to day 30
| Intervention | percentage with plt engraftment, day 30 (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 58 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Median) |
|---|---|
| Decitabine + Bone Marrow Transplant | 141 |
Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Mean) |
|---|---|
| Decitabine + Bone Marrow Transplant | 16 |
3 reviews available for busulfan and Infection
| Article | Year |
|---|---|
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2002 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Androgens; Anemia; Animals; Blood Cell Count; Blood C | 1971 |
8 trials available for busulfan and Infection
| Article | Year |
|---|---|
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; De | 2020 |
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
Topics: Administration, Intravenous; Adult; Aged; Busulfan; Female; Humans; Infections; Male; Melphalan; Mid | 2018 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; | 2009 |
CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma.
Topics: Antigens, CD34; Busulfan; Child; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplan | 2011 |
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2003 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bilirubin; Bone Marrow Transplantation; Busulfan; Child; Creatinine; Cyclophospha | 1994 |
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1996 |
24 other studies available for busulfan and Infection